Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$607.51 USD

607.51
2,463,120

+58.20 (10.60%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $604.00 -3.51 (-0.58%) 4:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks News

McKesson (MCK) Q4 Earnings Miss, Revenues Beat Estimates

McKesson's (MCK) fiscal fourth-quarter 2022 results benefit from segmental growth.

McKesson (MCK) Lags Q4 Earnings Estimates

McKesson (MCK) delivered earnings and revenue surprises of -3.80% and 3.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Medical Product Stocks' Earnings May 5 Roster: MCK, CAH & PODD

The Medical Product companies' quarterly results are likely to reflect base business recovery. Let's see how MCK, CAH and PODD are poised ahead of their earnings releases.

McKesson (MCK) to Report Q4 Earnings: What's in the Cards?

McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.

Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?

Style Box ETF report for CLRG

McKesson (MCK) Earnings Expected to Grow: Should You Buy?

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

McKesson (MCK) Stock Sinks As Market Gains: What You Should Know

McKesson (MCK) closed the most recent trading day at $317.31, moving -0.27% from the previous trading session.

Is IQ Chaikin U.S. Large Cap ETF (CLRG) a Strong ETF Right Now?

Smart Beta ETF report for CLRG

McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Illumina (ILMN) Hurt by Rising Costs, Tough Competition

Regulatory complications are raising the legal expenses for Illumina (ILMN), thereby building pressure on the bottom line.

Here's Why You Should Retain Phibro (PAHC) Stock For Now

Investors are optimistic about Phibro (PAHC) owing to the robust performances by its Animal Health and Mineral Health segments.

Integer Holdings' (ITGR) Latest Buyout to Expand Its Footprint

Integer Holdings' (ITGR) buyout of Aran Biomedical is set to expand its presence in high-growth markets as well as enhance its product offerings.

Masimo's (MASI) Sound United Buyout to Boost Product Portfolio

Masimo's (MASI) completion of Sound United's buyout to help enhance the former's extended portfolio of hospital and home medical technology solutions.

Illumina (ILMN) Launches Genomic Solution Hub in Brazil

Illumina's (ILMN) customers and partners in Brazil currently span basic research, applied markets to clinical labs and healthcare institutions.

NEOGEN (NEOG) Adds to Prozap Insect Control Product Line-up

NEOGEN's (NEOG) latest Prozap Protectus Pour-On Insecticide- IGR product relieves cattle from infestations.

Here's Why You Should Hold on to Cardiovascular Systems (CSII)

Investors are optimistic about Cardiovascular Systems' (CSII) robust international growth and upcoming launches.

Here's Why You Should Retain SmileDirectClub (SDC) For Now

Investors are optimistic about SmileDirectClub's (SDC) series of cutting-edge innovation, strategic distribution and insurance partnerships.

Bruker (BRKR) Unveils New Imaging Tools for Cancer Research

Bruker's (BRKR) latest innovation for cancer research is likely to strengthen the company's opportunities in proteomics and spatial biology.

IDEXX (IDXX) CAG Sales Gain Traction, FX Headwind Persists

IDEXX (IDXX) has been witnessing continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.

Here's Why You Should Retain Boston Scientific (BSX) For Now

Investors are optimistic about Boston Scientific's (BSX) robust organic sales and strategic buyouts.

Merit Medical's (MMSI) SCOUT Bx Delivery System Gets FDA Nod

Merit Medical's (MMSI) receipt of FDA clearance for the SCOUT Bx system can streamline treatment for cancer patients.

Alcon (ALC) Stock Rallies 4.7% Since Posting Q4 Earnings Beat

Alcon (ALC) stock rallies on robust growth across all Surgical and Vision Care sales categories.

Quidel Corporation (QDEL) Reports Solid Preliminary Q1 Revenues

Quidel's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued robust sales of its SARS-related products.

Here's Why You Should Retain Thermo Fisher (TMO) For Now

Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.

Here's Why You Should Hold on to Walgreens Boots (WBA) For Now

Investors are optimistic about Walgreens (WBA) owing to the recent product launches.